CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 592,792	$ 9,724,052	$ 81,413,212	$ 55,638,769	$ 147,368,825
Beginning balance, shares at Dec. 31, 2020	592,791,712
Contributions		791,610		4,176,800	4,968,410
Distributions			(30,054,155)	(8,831,693)	(38,885,848)
Net loss			37,762,136	13,116,866	50,879,002
Ending balance, value at Mar. 31, 2021	$ 592,792	10,515,662	89,121,193	64,100,742	164,330,389
End balance, shares at Mar. 31, 2021	592,791,712
Contributions		1,243,686		4,821,304	6,064,990
Distributions			(30,785,270)	(8,775,526)	(39,560,796)
Net loss			27,059,401	2,618,644	29,678,045
Ending balance, value at Jun. 30, 2021	$ 592,792	11,759,348	85,395,324	62,765,164	160,512,628
End balance, shares at Jun. 30, 2021	592,791,712
Contributions				1,488,478	1,488,478
Distributions			(21,694,166)	(1,542,930)	(23,237,096)
Net loss			53,793,277	20,700,975	74,494,252
Ending balance, value at Sep. 30, 2021	$ 592,792	11,759,348	117,494,435	83,411,687	213,258,262
End balance, shares at Sep. 30, 2021	592,791,712
Beginning balance, value at Dec. 31, 2021	$ 592,792	11,742,891	102,315,623	76,929,704	191,581,010
Beginning balance, shares at Dec. 31, 2021	592,791,712
Contributions				3,869,201	3,869,201
Distributions			(27,114,936)	(5,738,045)	(32,852,981)
Net loss			21,442,843	3,383,288	24,826,131
Ending balance, value at Mar. 31, 2022	$ 592,792	11,742,891	96,643,530	78,444,148	187,423,361
End balance, shares at Mar. 31, 2022	592,791,712
Reverse acquisition with Clinigence	$ 50,961	446,780,842		194,747	447,026,550
Reverse acquisition with Clinigence , shares	50,961,109
Notes payable converted to common stock	$ 2,623	4,062,749			4,065,372
Notes payable converted to common stock, shares	2,622,819
Common stock issued for exercise of warrants	$ 2,147	4,116,994			4,119,141
Common stock issued for exercise of warrants , shares	2,147,252
Common stock issued for exercise of options	$ 312	644,662			644,974
Common stock issued for exercise of options , shares	312,019
Stock-based compensation	$ 83	54,083			54,166
Stock-based compensation, shares	83,547
Deconsolidation of Real Estate Entities			(6,466,946)	(32,336,946)	(38,803,892)
Contributions				861,916	861,916
Distributions			(7,341,202)	(7,637,993)	(14,979,195)
Net loss			(19,284,846)	(4,713,304)	(23,998,150)
Ending balance, value at Jun. 30, 2022	$ 648,918	467,402,221	63,550,536	34,812,568	566,414,243
End balance, shares at Jun. 30, 2022	648,918,458
Beginning balance, value at Mar. 31, 2022	$ 592,792	11,742,891	96,643,530	78,444,148	187,423,361
Beginning balance, shares at Mar. 31, 2022	592,791,712
Ending balance, value at Sep. 30, 2022	$ 649,770	468,802,618	(358,967,267)	22,042,881	132,528,002
End balance, shares at Sep. 30, 2022	649,770,069
Beginning balance, value at Jun. 30, 2022	$ 648,918	467,402,221	63,550,536	34,812,568	566,414,243
Beginning balance, shares at Jun. 30, 2022	648,918,458
Notes payable converted to common stock	$ 852	1,319,148			1,320,000
Notes payable converted to common stock, shares	851,611
Stock-based compensation		81,249			81,249
Contributions				94,260	94,260
Distributions				(2,141,198)	(2,141,198)
Net loss			(422,517,803)	(10,722,749)	(433,240,552)
Ending balance, value at Sep. 30, 2022	$ 649,770	$ 468,802,618	$ (358,967,267)	$ 22,042,881	$ 132,528,002
End balance, shares at Sep. 30, 2022	649,770,069